BAUSCH HEALTH AMERICAS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: 3.1K

Market Cap: -

Website: http://www.bauschhealth.com

Clinical Trials

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: 210 mg brodalumab
Drug: 140 mg brodalumab
Drug: Placebo

First Posted Date: 2013-12-31

Last Posted Date: 2020-08-20

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 484

Registration Number: NCT02024646

Locations: 🇷🇺
Research Site, Voronezh, Russian Federation

EYEFILL® C. -US Viscoelastic Clinical Investigation

Not Applicable

Completed

Conditions: Cataract

Interventions: Device: Healon® Viscoelastic (CONTROL)
Device: EYEFILL® C.-US Viscoelastic

First Posted Date: 2013-12-31

Last Posted Date: 2020-09-04

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 262

Registration Number: NCT02024711

Locations: 🇺🇸
Shasta Eye Medical Group, Redding, California, United States
🇺🇸
Great Lakes Eye Care, Saint Joseph, Michigan, United States
🇺🇸
Newsom Eye and Laser Center, Sebring, Florida, United States

and more 5 locations

12-Week Study of Plecanatide for CIC (The CIC3 Study)

Phase 3

Completed

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: Placebo
Drug: Plecanatide
Drug: Bisacodyl

First Posted Date: 2013-11-13

Last Posted Date: 2019-12-26

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 1394

Registration Number: NCT01982240

Locations: 🇨🇦
Synergy Research Site, St-Romuald, Quebec, Canada

Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)

Phase 2

Completed

Conditions: Constipation

Interventions: Drug: SP-333 1 mg
Drug: SP-333 3 mg
Drug: SP-333 6 mg
Drug: Placebo

First Posted Date: 2013-11-13

Last Posted Date: 2021-05-07

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 292

Registration Number: NCT01983306

Locations: 🇺🇸
Synergy Research Site, San Antonio, Texas, United States

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Brodalumab

First Posted Date: 2013-09-09

Last Posted Date: 2017-04-10

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 31

Registration Number: NCT01937260

Locations: 🇳🇿
Research Site, Grafton, Auckland, New Zealand

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Phase 3

Completed

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: Plecanatide

First Posted Date: 2013-08-09

Last Posted Date: 2019-07-02

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 2370

Registration Number: NCT01919697

Locations: 🇨🇦
Synergy Research Site, St-Romuald, Quebec, Canada

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

Phase 2

Completed

Conditions: Liver Cirrhosis

Interventions: Drug: Rifaximin SSD 80 mg SER tablet
Drug: Rifaximin SSD 80 mg IR tablet
Drug: Rifaximin SSD 40 mg SER tablet
Drug: Rifaximin SSD 40 mg IR tablet
Drug: Placebo
Drug: Rifaximin SSD 80mgIR/80mgSER tablet

First Posted Date: 2013-07-22

Last Posted Date: 2019-10-23

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 420

Registration Number: NCT01904409

Locations: 🇷🇺
Salix Investigative Site, Stavropol, Russian Federation
🇺🇸
Salix Investigational Site, Richmond, Virginia, United States

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Phase 4

Terminated

Conditions: Hepatic Encephalopathy

Interventions: Drug: Placebo
Drug: Rifaximin

First Posted Date: 2013-05-03

Last Posted Date: 2024-01-09

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 6

Registration Number: NCT01846663

Locations: 🇺🇸
Loma Linda University Medical Center Transplantation Institute, Loma Linda, California, United States
🇺🇸
University of Southern Califorina Keck School Of Medicine, Los Angeles, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 22 locations

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Phase 4

Completed

Conditions: Hepatic Encephalopathy
Cirrhosis

Interventions: Drug: Rifaximin
Drug: Lactulose

First Posted Date: 2013-04-29

Last Posted Date: 2019-09-09

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 222

Registration Number: NCT01842581

Locations: 🇺🇸
The Center for Liver and Biliary Disease, Baltimore, Maryland, United States
🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸
Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States

and more 33 locations

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

Phase 2

Completed

Conditions: Irritable Bowel Syndrome Characterized by Constipation

Interventions: Drug: Placebo
Drug: Plecanatide

First Posted Date: 2012-11-06

Last Posted Date: 2019-05-28

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 428

Registration Number: NCT01722318

Locations: 🇺🇸
San Marcus Research Clinic, Inc., Miami, Florida, United States
🇺🇸
Genoma Research Group, Inc., Miami, Florida, United States
🇺🇸
South Medical Research Group, Inc., Miami, Florida, United States

and more 94 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy